Clopidogrel Versus Ticagrelor or Prasugrel After Primary Percutaneous Coronary Intervention According to CYP2C19 Genotype: A POPular Genetics Subanalysis

Daniel M F Claassens; Thomas O Bergmeijer; Gerrit J A Vos; Renicus S Hermanides; Arnoud W J van 't Hof; Pim van der Harst; Emanuele Barbato; Carmine Morisco; Richard M Tjon Joe Gin; Folkert W Asselbergs; Arend Mosterd; Jean-Paul R Herrman; Willem J M Dewilde; Paul W A Janssen; Johannes C Kelder; Bakhtawar K Mahmoodi; Vera H M Deneer; Jurriën M Ten Berg

doi:10.1161/CIRCINTERVENTIONS.120.009434

Clopidogrel Versus Ticagrelor or Prasugrel After Primary Percutaneous Coronary Intervention According to CYP2C19 Genotype: A POPular Genetics Subanalysis

Circ Cardiovasc Interv. 2021 Apr;14(4):e009434. doi: 10.1161/CIRCINTERVENTIONS.120.009434. Epub 2021 Mar 16.

Authors

Daniel M F Claassens^#^{1

2}, Thomas O Bergmeijer^#¹, Gerrit J A Vos¹, Renicus S Hermanides², Arnoud W J van 't Hof^{2

3

4

5}, Pim van der Harst^{6

7}, Emanuele Barbato^{8

9}, Carmine Morisco⁸, Richard M Tjon Joe Gin¹⁰, Folkert W Asselbergs^{7

11

12}, Arend Mosterd¹³, Jean-Paul R Herrman¹⁴, Willem J M Dewilde¹⁵, Paul W A Janssen¹, Johannes C Kelder¹, Bakhtawar K Mahmoodi¹, Vera H M Deneer^{16

17}, Jurriën M Ten Berg^{1

5}

Affiliations

¹ Department of Cardiology, St. Antonius Hospital, Nieuwegein, the Netherlands (D.M.F.C., T.O.B., G.J.A.V., P.W.A.J., J.C.K., B.K.M., J.M.t.B.).
² Department of Cardiology, Isala Hospital, Zwolle, the Netherlands (D.M.F.C., R.S.H., A.W.J.v.H.).
³ Department of Cardiology, University Medical Center Maastricht, the Netherlands (A.W.J.v.H.).
⁴ Department of Cardiology, Zuyderland Medical Center, Heerlen, the Netherlands (A.W.J.v.H.).
⁵ Cardiovascular Research Institute Maastricht (CARIM), the Netherlands (A.W.J.v.H., J.M.t.B.).
⁶ Department of Cardiology, University Medical Center Groningen, the Netherlands (P.v.d.H.).
⁷ Department of Cardiology, Division Heart & Lungs, University Medical Center Utrecht (P.v.d.H., F.W.A.), Utrecht University, the Netherlands.
⁸ Department of Advanced Biomedical Sciences, University of Naples Federico II, Italy (E.B., C.M.).
⁹ Cardiovascular Research Center, Onze lieve Vrouwe Hospital, Aalst, Belgium (E.B.).
¹⁰ Department of Cardiology, Rijnstate Hospital, Arnhem, the Netherlands (R.M.T.J.G.).
¹¹ Institute of Cardiovascular Science, Faculty of Population Health Sciences (F.W.A.), University College London, United Kingdom.
¹² Health Data Research UK and Institute of Health Informatics (F.W.A.), University College London, United Kingdom.
¹³ Department of Cardiology, Meander Medical Center, Amersfoort, the Netherlands (A.M.).
¹⁴ Department of Cardiology, Onze Lieve Vrouwe Gasthuis, Amsterdam, the Netherlands (J-.P.R.H.).
¹⁵ Department of Cardiology, Imelda hospital, Bonheiden, Belgium (W.J.M.D.).
¹⁶ Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences (V.H.M.D.), Utrecht University, the Netherlands.
¹⁷ Division Laboratories, Department of Clinical Pharmacy, Pharmacy and Biomedical Genetics, University Medical Center Utrecht, the Netherlands (V.H.M.D.).

^# Contributed equally.

PMID: 33722066
DOI: 10.1161/CIRCINTERVENTIONS.120.009434

Abstract

[Figure: see text].

Trial registration: ClinicalTrials.gov NCT01761786.

Keywords: acute coronary syndrome; clopidogrel; genetic testing; myocardial infarction; percutaneous coronary intervention; pharmacogenetics; ticagrelor.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Acute Coronary Syndrome* / drug therapy
Acute Coronary Syndrome* / genetics
Clopidogrel / adverse effects
Cytochrome P-450 CYP2C19 / genetics
Genotype
Humans
Percutaneous Coronary Intervention* / adverse effects
Platelet Aggregation Inhibitors / adverse effects
Prasugrel Hydrochloride / adverse effects
Ticagrelor / adverse effects
Treatment Outcome

Substances

Platelet Aggregation Inhibitors
Clopidogrel
CYP2C19 protein, human
Cytochrome P-450 CYP2C19
Prasugrel Hydrochloride
Ticagrelor

Associated data

ClinicalTrials.gov/NCT01761786